" /> Derazantinib - CISMeF





Preferred Label : Derazantinib;

NCIt definition : An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. Derazantinib binds to and potently inhibits the activity of FGFR subtypes 1, 2 and 3. This may result in the inhibition of FGFR-mediated signal transduction pathways, tumor cell proliferation, tumor angiogenesis and tumor cell death in FGFR-overexpressing tumor cells. FGFR, a receptor tyrosine kinase, is upregulated in many tumor cell types and plays a key role in tumor cellular proliferation, differentiation, angiogenesis and survival.;

UNII : N9B0H171MJ;

InChIKey : KPJDVVCDVBFRMU-AREMUKBSSA-N;

CAS number : 1234356-69-4; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1234356-69-4 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Molecule name : ARQ 087; ARQ-087;

NCI Metathesaurus CUI : CL445613;

ChEBI ID : CHEBI:63453;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
16/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.